

**Supplementary Table 2.** Percentage of subjects with rSBA titers  $\geq$  the cut-off values of 1:8 and 1:128 prior to and one month after vaccination, analysis by country, GlaxoSmithKline rSBA assay (ATP cohort for immunogenicity).

GSK rSBA titers										
Group	Tp	Panama			Thailand			Philippines		
		N	% $\geq$ 1:8 (95% CI)	% $\geq$ 1:128 (95% CI)	N	% $\geq$ 1:8 (95% CI)	% $\geq$ 1:128 (95% CI)	N	% $\geq$ 1:8 (95% CI)	% $\geq$ 1:128 (95% CI)
<b>rSBA-MenA</b>										
<b>ACWY-A</b>	Pre	110	90.0 (82.8, 94.9)	86.4 (78.5, 92.2)	104	95.2 (89.1, 98.4)	89.4 (81.9, 94.6)	106	92.5 (85.7, 96.7)	79.2 (70.3, 86.5)
	Post	114	100 (96.8, 100)	100 (96.8, 100)	117	100 (96.9, 100)	100 (96.9, 100)	128	100 (97.2, 100)	100 (97.2, 100)
<b>ACWY-B</b>	Pre	112	92.9 (86.4, 96.9)	88.4 (81.0, 93.7)	112	98.2 (93.7, 99.8)	92.9 (86.4, 96.9)	104	96.2 (90.4, 98.9)	85.6 (77.3, 91.7)
	Post	107	100 (96.6, 100)	100 (96.6, 100)	118	100 (96.9, 100)	100 (96.9, 100)	118	100 (96.9, 100)	100 (96.9, 100)
<b>Men-PS</b>	Pre	108	97.2 (92.1, 99.4)	95.4 (89.5, 98.5)	98	94.9 (88.5, 98.3)	85.7 (77.2, 92.0)	104	93.3 (86.6, 97.3)	84.6 (76.2, 90.9)
	Post	112	100 (96.8, 100)	100 (96.8, 100)	121	100 (97.0, 100)	100 (97.0, 100)	123	100 (97.0, 100)	100 (97.0, 100)
<b>rSBA-MenC</b>										
<b>ACWY-A</b>	Pre	110	43.6 (34.2, 53.4)	30.9 (22.4, 40.4)	126	61.1 (52.0, 69.7)	36.5 (28.1, 45.6)	115	74.8 (65.8, 82.4)	46.1 (36.8, 55.6)
	Post	115	100 (96.8, 100)	100 (96.8, 100)	129	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	100 (97.2, 100)
<b>ACWY-B</b>	Pre	113	47.8 (38.3, 57.4)	31.9 (23.4, 41.3)	125	64.8 (55.8, 73.1)	42.4 (33.6, 51.6)	112	69.6 (60.2, 78.0)	54.5 (44.8, 63.9)
	Post	112	100 (96.8, 100)	100 (96.8, 100)	129	100 (97.2, 100)	100 (97.2, 100)	129	100 (97.2, 100)	100 (97.2, 100)

<b>Men-PS</b>	Pre	119	41.2 (32.2, 50.6)	31.1 (22.9, 40.2)	127	67.7 (58.8, 75.7)	50.4 (41.4, 59.4)	115	77.4 (68.7, 84.7)	50.4 (41.0, 59.9)
	Post	114	100 (96.8, 100)	99.1 (95.2, 100)	128	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	99.2 (95.8, 100)
<b>rSBA-MenW-135</b>										
<b>ACWY-A</b>	Pre	114	76.3 (67.4, 83.8)	60.5 (50.9, 69.6)	123	89.4 (82.6, 94.3)	76.4 (67.9, 83.6)	106	93.4 (86.9, 97.3)	76.4 (67.2, 84.1)
	Post	116	100 (96.9, 100)	100 (96.9, 100)	129	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	100 (97.2, 100)
<b>ACWY-B</b>	Pre	107	86.9 (79.0, 92.7)	71.0 (61.5, 79.4)	119	82.4 (74.3, 88.7)	76.5 (67.8, 83.8)	107	88.8 (81.2, 94.1)	68.2 (58.5, 76.9)
	Post	113	100 (96.8, 100)	100 (96.8, 100)	129	100 (97.2, 100)	100 (97.2, 100)	128	100 (97.2, 100)	100 (97.2, 100)
<b>Men-PS</b>	Pre	116	84.5 (76.6, 90.5)	75.0 (66.1, 82.6)	122	82.8 (74.9, 89.0)	68.9 (59.8, 76.9)	107	92.5 (85.8, 96.7)	68.2 (58.5, 76.9)
	Post	114	100 (96.8, 100)	100 (96.8, 100)	128	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	99.2 (95.8, 100)
<b>rSBA-MenY</b>										
<b>ACWY-A</b>	Pre	119	86.6 (79.1, 92.1)	78.2 (69.6, 85.2)	129	93.8 (88.1, 93.7)	83.7 (76.2, 89.6)	115	96.5 (91.3, 99.0)	92.2 (85.7, 96.4)
	Post	116	100 (96.9, 100)	100 (96.9, 100)	129	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	100 (97.2, 100)
<b>ACWY-B</b>	Pre	115	89.6 (82.5, 94.5)	80.0 (71.5, 86.9)	128	94.5 (89.1, 97.8)	86.7 (79.6, 92.1)	116	98.3 (93.9, 99.8)	90.5 (83.7, 95.2)
	Post	113	100 (96.8, 100)	100 (96.8, 100)	129	100 (97.2, 100)	100 (97.2, 100)	129	100 (97.2, 100)	100 (97.2, 100)
<b>Men-PS</b>	Pre	120	88.3 (81.2, 93.5)	82.5 (74.5, 88.8)	128	94.5 (89.1, 97.8)	88.3 (81.4, 93.3)	116	94.0 (88.0, 97.5)	87.1 (79.6, 92.6)
	Post	115	100 (96.8, 100)	100 (96.8, 100)	128	100 (97.2, 100)	100 (97.2, 100)	130	100 (97.2, 100)	100 (97.2, 100)

Footnote: ACWY-A=subjects vaccinated with MenACWY-TT Lot A

ACWY-B=subjects vaccinated with MenACWY-TT Lot B

Men-PS=subjects vaccinated with Men-PS

GSK=GlaxoSmithKline

Tp=timepoint

N=number of subjects with available results

%=percentage of subjects with titer within the specified range

95% CI=95% confidence interval

Pre=pre-vaccination at month 0

Post=post-vaccination at month 1